Cinvanti (Aprepitant) Patent Expiration, LOE Window & CMS Spending

Cinvanti (Aprepitant) by Heron Therapeutics: FDA Orange Book LOE 2035-09-18, 3 AB generics, $16.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorHeron Therapeutics
FDA Application & PathwayN209296 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2035-09-18
Orange Book Patents (*PED Extensions)13 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$16.0M
2024 Medicare Part D Spend$289K
2024 Medicaid Spend$15.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel